Myelofibrosis Clinical Trial
Official title:
Study of Fludarabine Based Conditioning for Allogeneic Stem Cell Transplantation for Myelofibrosis
Stem cell transplantation is used to treat may types of diseases. There a 2 types of
transplants, conventional (very intense) and reduced intensity-non-myeloablative, also
called mini-transplants.
This study proposes to use a conditioning regimen for allogeneic transplantation along with
a reduced intensity transplant. Conditioning regiment is the name for the combination of
chemotherapy drugs that is given to patients before receiving a transplantation of donor
stem cells. It is hoped that the regimen designed for this study proves to be less toxic and
has an equal or better anticancer effect than the regimens that are normally used. The
regimen being used is a combination of two chemotherapy drugs, fludarabine and melphalan.
This regimen has been studied in recipients of matched sibling transplants and in recipients
of alternative donor stem cells in other hematologic malignancies. Those subjects, who
receive stem cells from an unrelated donor, will also receive and additional drug called ATG
or anti thymocyte globulin. ATG suppresses the immune system, thus reducing the chances for
the recipient rejecting the transplant (graft).
The purpose of this study is to observe if reduced intensity transplants can be used to
allow engraftment or "take" of the donor's bone marrow. Studies conducted in the past show
this type of transplant is much less toxic than traditional bone marrow transplants. Reduced
intensity transplants may be better tolerated by patients who may experience serious side
effects from standard (very intense) stem cell transplant.
The study has been recently amended to follow all subjects for survival.
This study is designed as a single arm Phase II clinical trial in patients with
myelofibrosis who are eligible for transplantation from a related donor or from an unrelated
donor source. Patients will be accrued into two separate strata defined by donor type. Each
of the two strata will be analyzed separately.
Patients will be followed yearly from time of enrollment into the study to assess clinical
response and overall, progression and event free survival, as well as incidence and degree
of acute and chronic GVHD. We will estimate cumulative survival and transplant related
mortality in patients enrolled in each of the two strata.
;
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02916979 -
Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG
|
Phase 1 | |
| Not yet recruiting |
NCT06345495 -
High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly
|
Phase 2 | |
| Terminated |
NCT04866056 -
Jaktinib and Azacitidine In Treating Patients With MDS With MF or MDS/MPN With MF.
|
Phase 1/Phase 2 | |
| Completed |
NCT02784496 -
Long-Term Side Effects of Ruxolitinib in Treating Patients With Myelofibrosis
|
Phase 2 | |
| Completed |
NCT00069680 -
Genetic Analysis of Gray Platelet Syndrome
|
||
| Active, not recruiting |
NCT04097821 -
Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis Patients
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03289910 -
Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia
|
Phase 2 | |
| Completed |
NCT04666025 -
SARS-CoV-2 Donor-Recipient Immunity Transfer
|
||
| Not yet recruiting |
NCT06397313 -
RVU120 in Patients With Intermediate or High-risk, Primary or Secondary Myelofibrosis
|
Phase 2 | |
| Not yet recruiting |
NCT06024915 -
A Study to Evaluate Drug-Drug Interaction of TQ05105 Tablets
|
Phase 1 | |
| Terminated |
NCT02877082 -
Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients
|
Phase 2 | |
| Completed |
NCT02910258 -
Interferon-pegyle α2a Efficiency and Tolerance in Myelofibrosis
|
||
| Completed |
NCT00975975 -
Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer
|
Phase 2 | |
| Completed |
NCT00997386 -
Reduced Intensity Allogeneic PBSCT to Treat Hematologic Malignancies and Hematopoietic Failure States
|
Phase 2 | |
| Completed |
NCT00666549 -
Research Tissue Bank
|
||
| Terminated |
NCT00393380 -
Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated Donor
|
Phase 2 | |
| Terminated |
NCT00522990 -
Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias
|
Phase 1/Phase 2 | |
| Completed |
NCT00606437 -
Total Body Irradiation With Fludarabine Followed by Combined Umbilical Cord Blood (UCB) Transplants
|
Phase 1 | |
| Active, not recruiting |
NCT03952039 -
An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib
|
Phase 3 | |
| Not yet recruiting |
NCT04709458 -
Safety and Early Efficacy Study of TBX-2400 in Patients With AML or Myelofibrosis
|
Phase 1 |